Skip to main content
David Maron, MD, Cardiology, Stanford, CA

David J Maron MD

Preventive Cardiology


Physician

Join to view full profile
  • 300 Pasteur DrStanford, CA 94305

  • Phone+1 650-723-4000

Dr. Maron is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Maron is the C.F. Rehnborg Professor of Medicine and Chief of the Stanford Prevention Research Center at Stanford University. He received his undergraduate degree from Stanford and his medical degree from the University of Southern California. He trained in internal medicine at UCLA, then returned to Stanford where he was a Robert Wood Johnson Clinical Scholar. He remained at Stanford to complete cardiology fellowship training. After a brief stint in private practice in Santa Monica, he joined the faculty at Vanderbilt in 1993 as Director of Preventive Cardiology and rose through the ranks to Professor. He returned to Stanford in 2014.

    Dr. Maron’s research is focused on the primary and secondary prevention of coronary artery disease. He was a member of the team that designed the VA-funded COURAGE trial that tested the benefit of PCI added to guideline-directed medical therapy in patients with stable coronary artery disease. He was co-chair and principal investigator of the ISCHEMIA trial, an NIH-funded study that tested the benefits of an initial invasive approach compared with a conservative approach in patients with stable coronary artery disease. He is co-chair of the TRANSFORM trial comparing conventional risk factor-based care with atherosclerosis stage-based care in a high-risk asymptomatic population.

    He helped develop an AI algorithm to measure coronary artery calcium in nongated chest CT scans. This algorithm is used in over 100 hospitals for opportunistic screening for incidental coronary artery calcium. He sees patients in the Stanford Preventive Cardiology clinic and is president-elect of the American Society for Preventive Cardiology.

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Cardiovascular Disease, 1989 - 1991
  • Stanford Health Care
    Stanford Health CareResidency, Preventive Cardiology Fellowship and Robert Wood Johnson Clinical Scholar, 1984 - 1986
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1981 - 1984
  • Keck School of Medicine of the University of Southern California
    Keck School of Medicine of the University of Southern CaliforniaClass of 1981

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1982 - 2027
  • TN State Medical License
    TN State Medical License 1993 - 2014
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
  • CMS Meaningful Use Stage 1 Certification StarPanel, Vanderbilt University, 2012, 2014, 2016-2017
  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Initial Invasive or Conservative Strategy for Stable Coronary Disease  
    David Maron, MD, The New England Journal of Medicine
  • Association of Sex with Severity of CAD, Ischemia, and Symptom Burden in Patients with Moderate or Severe Ischemia  
    Michael H Picard, Raymond Y Kwong, William E Boden, David J Maron, Judith S Hochman, JAMA Cardiology

Lectures

  • Preview From the Upcoming Ischemia Trial 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/27/2019
  • Personal Position Statement: “Patients With Stable Ischemic Heart Disease Are Best Managed Conservatively Until Truly Refractory Symptoms Develop 
    2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019

Authored Content

  • Initial Invasive or Conservative Strategy for Stable Coronary DiseaseApril 2020
  • Association of Sex with Severity of CAD, Ischemia, and Symptom Burden in Patients with Moderate or Severe IschemiaMarch 2020

Press Mentions

  • A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease
    A Promising Heart Drug Fails, Challenging a Long-Held Theory of DiseaseAugust 6th, 2026
  • HeartLung Technologies Sets New Milestone with Nine Accepted Abstracts at AHA 2025 Showcasing the Power of AI-CVD™
    HeartLung Technologies Sets New Milestone with Nine Accepted Abstracts at AHA 2025 Showcasing the Power of AI-CVD™October 22nd, 2025
  • 6 Drinks You Should Never Mix with Blood Pressure Medications
    6 Drinks You Should Never Mix with Blood Pressure MedicationsSeptember 18th, 2025

Professional Memberships

Other Languages

  • Spanish

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: